このポッドキャストについて 🔗

更新頻度:
biweekly
平均音声長:
42 minutes
ゲストインタビュー
英語
カナダ
38 エピソード
2025年5月15日から
episodic

このポッドキャストの内容 🔗

最新エピソード 🔗

What are the biggest gaps between psychedelic trials and what actually happens in the dosing room? And how might an Ayahuasca-inspired drug formulation affect shame and self-referential thinking? In this episode, we are joined by Dr. Helena Aicher, a research associate at the University of Zurich…

過去のエピソードを検索

The Integration Sessionの以前のエピソードを検索します。

以前のエピソード

Therapeutic touch is often used in psychedelic therapy, but what ethical guidelines and boundaries should researchers and therapists follow? What can we learn from patient perspectives about consent, and where to draw the line? In this episode, Dr. Rachel Ham joins us from Monash University in Mel…
Psychedelics are often described as capable of “rewiring the brain,” but this leaves out a more complex and elegant series of mechanisms beneath the cortex. This episode goes a layer deeper to explore specific brain regions and receptors that are less often talked about in psychedelic science, desp…
What does it actually mean, physically, for a brain to be conscious, and what can psychedelics teach us about it? Can consciousness extend beyond living things, including artificial intelligence? In this episode of The Integration Session, we're joined by Dr. Adam Barrett, Associate Professor in …
What can two decades of clinical research teach us about psilocybin's potential for treating obsessive-compulsive disorder (OCD)? In this episode, we sit down with Dr. Francisco Moreno, a pioneer in psychedelic-assisted treatment research, to trace the arc of his work - from his landmark 2006 trial…
Want to stay updated on the latest advancements in psychedelic science without reading lengthy scientific papers? Welcome back to Research Recap, where Elena breaks down three recent studies in psychedelic science, in a digestible format. This episode covers a phase IIa trial of short-acting intrav…
Psychedelic treatments are often celebrated for their antidepressant potential, but emerging research suggests their effects go beyond traditional mood improvement. These compounds appear to work on multiple levels, prompting researchers to propose a more accurate term: “antidistressant.”  But what…
Psychedelics and psychosis have long been intertwined. Historically, psychedelics were more often called ‘psychotomimetics’ or compounds that temporarily mimic the symptoms of psychosis. But today, rather than modelling psychopathology, psychedelics are more often viewed as therapeutic tools in psy…
One of the most talked-about psychedelics in recent years is ibogaine, especially amidst recent policy shifts that aim to fast-track research progress in this area. While early evidence shows therapeutic potential for opioid addiction and PTSD in veterans, legitimate concerns remain regarding safet…
One of the most pressing challenges in psychedelic science is the placebo problem: the intense subjective effects of psychedelics cause functional unblinding and amplify expectancy effects, undermining the integrity of gold-standard randomized controlled trials. In this episode of The Integration S…
免責: このページに埋め込まれているポッドキャストとアートワークは The Centre for Psychedelics Health and Research からのものであり、その所有者の所有物であり、Listen Notes, Inc. と提携または承認されていません。